摘要
目的研究基因重组人生长激素治疗特发性矮小症患儿的效果及对IGF-1水平、糖脂代谢的影响。方法选取2021年1月至2024年1月本院收治的120例特发性矮小症患儿作为研究对象,将其随机分为对照组和观察组,各60例。对照组采用常规治疗,观察组在对照组基础上增加基因重组人生长激素治疗。比较两组的临床疗效、生长指标、胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)水平、糖脂代谢指标及不良反应发生情况。结果观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的身高、生长速度均高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的IGF-1、IGFBP-3水平高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的空腹血糖(FBG)、餐后2 h血糖(2 h PG)、总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平比较,差异无统计学意义(P>0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论基因重组人生长激素治疗特发性矮小症患儿的效果显著,可促进身高生长,提高IGF-1水平,不影响糖脂代谢过程,且治疗安全性良好。
Objective To study the effect of recombinant human growth hormone in the treatment of children with idiopathic dwarfism and its influences on IGF-1 level and glucose and lipid metabolism.Methods A total of 120 children with idiopathic dwarfism admitted to our hospital from January 2021 to January 2024 were selected as the research objects.The children were randomly divided into control group and observation group,with 60 cases in each group.The control group was treated with conventional therapy,and the observation group was treated with recombinant human growth hormone on the basis of the control group.The clinical efficacy,growth indicators,insulin-like growth factor-1(IGF-1),insulin-like growth factor binding protein-3(IGFBP-3)levels,glucose and lipid metabolism indicators and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the height and growth rate of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of IGF-1 and IGFBP-3 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,there were no significant differences in the levels of fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)between the two groups(P>0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant human growth hormone is effective in the treatment of children with idiopathic dwarfism,which can promote height growth and increase IGF-1 level,without affecting the process of glucose and lipid metabolism,and the treatment safety is good.
作者
赵秀莲
许亚萍
于金凤
ZHAO Xiulian;XU Yaping;YU Jinfeng(Pediatrics Department,Yanliang District People's Hospital,Xi'an 710089,China)
出处
《临床医学研究与实践》
2025年第25期110-113,共4页
Clinical Research and Practice
关键词
特发性矮小症
基因重组人生长激素
胰岛素样生长因子-1
糖脂代谢
idiopathic dwarfism
recombinant human growth hormone
insulin-like growth factor-1
glucose and lipid metabolism
作者简介
赵秀莲(1979-),女,副主任医师,学士。研究方向:儿童生长发育;通讯作者:于金凤,E-mail:471051036@qq.com.
